British Journal of Haematology

Inclusion criteria of currently enrolling T-cell engaging trials in multiple myeloma: Should we be focusing on lines of prior therapy? 2023

Drug class refractoriness, not number of prior lines of therapy, properly classify patients with relapsed and refractory multiple myeloma.  200:824-827. 2023

Patients with sickle cell disease who develop end-stage kidney disease continue to experience poor survival — A 19-year United States Renal Data System study.  199:e43-e47. 2022

An evaluation of cardiopulmonary endurance and muscular strength in adults living with sickle cell disease.  199:597-602. 2022

Classical and non-classical phenotypes of Erdheim–Chester disease: Correlating clinical, radiographic and genotypic findings.  199:454-457. 2022

Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study.  199:355-365. 2022

Hypomethylating agent/venetoclax versus intensive chemotherapy in adults with relapsed or refractory acute myeloid leukaemia.  198:e35-e37. 2022

How I treat triple-class refractory multiple myeloma.  198:244-256. 2022

First report of novel heterozygous WRAP53 p.Ala522Glyfs*8 mutation associated dyskeratosis congenita.  196:e27-e29. 2022

Mimics of Erdheim–Chester disease.  196:984-994. 2022

Treatment of immune thrombocytopenia with eltrombopag in patients who had and who had not received prior rituximab: post-hoc analysis of the EXTEND study.  196:448-452. 2022

Gaps in the diagnosis and management of iron overload in sickle cell disease: a ‘real-world’ report from the GRNDaD registry.  195:e157-e160. 2021

Long-term biological effects in sickle cell disease: insights from a post-crizanlizumab study.  195:e150-e153. 2021

Which adults with sickle cell disease need an evaluation for pulmonary embolism?.  195:447-455. 2021

Impact of t(11;14) as a sole and concomitant abnormality on outcomes in multiple myeloma.  195:e113-e116. 2021

Generalization of a genetic risk score for time to first albuminuria in children with sickle cell anaemia: SCCRIP cohort study results.  194:469-473. 2021

Autologous stem cell transplantation in the age of ANDROMEDA.  193:865-866. 2021

Concomitant Erdheim-Chester disease and chronic myelomonocytic leukaemia: genomic insights into a common clonal origin.  187:e51-e54. 2019

Challenges and opportunities in the assessment of measurable residual disease in multiple myeloma.  186:807-819. 2019

Late mortality in blood or marrow transplant survivors with venous thromboembolism: report from the Blood or Marrow Transplant Survivor Study.  186:367-370. 2019

A population-based analysis of second primary malignancies in T-cell neoplasms.  185:338-342. 2019

Genetic characterization and therapeutic targeting of MYC-rearranged T cell acute lymphoblastic leukaemia.  185:169-174. 2019

T cell/histiocyte-rich large B cell lymphoma: incidence, demographic disparities, and long-term outcomes.  185:140-142. 2019

Incidence and outcomes of rare paediatric non-hodgkin lymphomas.  184:864-867. 2019

Novel findings from the multinational DOVE study on geographic and age-related differences in pain perception and analgesic usage in children with sickle cell anaemia.  184:1058-1061. 2019

Radiological imaging and bone marrow biopsy in staging of cutaneous B-cell lymphoma.  184:674-676. 2019

Revisiting fat embolism in sickle syndromes: diagnostic and emergency therapeutic measures.  186:e112-e115. 2019

Ticagrelor does not impact patient-reported pain in young adults with sickle cell disease: a multicentre, randomised phase IIb study.  184:269-278. 2019

Efficacy of biological agents in the treatment of Erdheim-Chester disease.  183:520-524. 2018

Adult disseminated Langerhans cell histiocytosis: incidence, racial disparities and long-term outcomes.  182:579-581. 2018

Second primary malignancy after multiple myeloma-population trends and cause-specific mortality.  182:513-520. 2018

Incidence and survival trends in mantle cell lymphoma.  181:703-706. 2018

Hydroxycarbamide for patients with silent cerebral infarcts: outcomes and patient preference.  181:145-148. 2018

Incidence and outcomes of paediatric myelodysplastic syndrome in the United States.  180:898-901. 2018

R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis.  180:534-544. 2018

Klinefelter syndrome and 47,XYY syndrome in children with B cell acute lymphoblastic leukaemia.  179:843-846. 2017

Increased prevalence of potential right-to-left shunting in children with sickle cell anaemia and stroke.  176:300-308. 2017

Management of relapsed and refractory childhood acute promyelocytic leukaemia: recommendations from an international expert panel.  175:588-601. 2016

Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies.  175:55-65. 2016

Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: Further results of the E1905 North American Leukemia Intergroup study.  172:384-391. 2016

Pre-transplant comorbidity burden and post-transplant chronic graft-versus-host disease.  171:411-416. 2015

Loss of RUNX1/AML1 arginine-methylation impairs peripheral T cell homeostasis.  170:859-873. 2015

Multi-centre validation of the prognostic value of the haematopoietic cell transplantation- specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation.  170:574-583. 2015

Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: A phase 1 study.  169:534-543. 2015

Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma.  169:219-227. 2015

REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia.  168:796-805. 2015

The role of FDG-PET/CT in the evaluation of residual disease in paediatric non-Hodgkin lymphoma.  168:845-853. 2015

Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy.  168:94-101. 2015

Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS.  167:62-68. 2014

Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes.  166:352-359. 2014

Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation.  163:205-213. 2013

Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens..  162:376-382. 2013

Ticlopidine-associated ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in 22 persons in Japan: A report from the Southern Network on Adverse Reactions (SONAR).  161:896-898. 2013

Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP).  160:538-546. 2013

Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: A phase I study.  162:693-701. 2013

Human immunodeficiency virus associated thrombotic thrombocytopenic purpura - favourable outcome with plasma exchange and prompt initiation of highly active antiretroviral therapy.  153:515-519. 2011

Overcoming HLA-DPB1 donor specific antibody-mediated haematopoietic graft failure.  151:94-96. 2010

Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia.  148:48-58. 2010

Impact of allogeneic haematopoietic stem cell transplantation in the outcome of Ph⁺ acute lymphoblastic leukaemia treated with an imatinib-containing regimen.  146:576-577. 2009

Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome.  145:101-106. 2009

Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia.  144:930-932. 2009

Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma.  143:268-273. 2008

Germinal center B (GCB) and non-GCB cell-like diffuse large B cell lymphomas have similar outcomes following autologous haematopoietic stem cell transplantation.  142:404-412. 2008

Cardiac and cardiovascular consequences after haematopoietic stem cell transplantation.  142:11-26. 2008

Abundant anti-apoptotic BCL-2 is a molecular target in leukaemias with t(4;11) translocation.  141:827-839. 2008

The MLL partial tandem duplication in acute myeloid leukaemia.  135:438-449. 2006

Histamine increases sickle erythrocyte adherence to endothelium.  132:512-522. 2006

A serine-rich glycoprotein of Streptococcus sanguis mediates adhesion to platelets via GPIb.  129:101-109. 2005

Pathology of bone marrow in human herpes virus-8 (HHV8)-associated multicentric Castleman disease.  127:585-591. 2004

Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma.  125:470-476. 2004

A recombinant bispecific single-chain Fv antibody against HLA class II and FcγRIII (CD16) triggers effective lysis of lymphoma cells.  125:167-179. 2004

Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia: A study of the Cancer and Leukaemia Group B.  124:275-288. 2004

N-linked sialyated sugar receptors support haematopoietic cell-osteoblast adhesions.  124:534-546. 2004

Late-effects among survivors of leukaemia and lymphoma during childhood and adolescence.  122:345-359. 2003

Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma.  118:799-808. 2002

Abnormal growth factor modulation of β1-integrin-mediated adhesion in chronic myelogenous leukaemia haematopoietic progenitors.  115:845-853. 2001

NON-MHC-restricted cytotoxic cells: Their roles in the control and treatment of leukaemias.  114:11-24. 2001

Hepatocyte growth factor is secreted by osteoblasts and cooperatively permits the survival of haematopoietic progenitors.  112:438-448. 2001

Human osteoblast-like cells and osteosarcoma cell lines synthesize macrophage inhibitory protein 1α in response to interleukin 1β and tumour necrosis factor α stimulation in vitro.  108:275-283. 2000

Syndecan-1 expression suppresses the level of myeloma matrix metalloproteinase-9.  104:365-373. 1999

V(H) gene usage by family members affected with chronic lymphocytic leukaemia.  107:616-624. 1999

Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma.  99:368-371. 1997

Comparison of benzimidazole nucleosides and ganciclovir on the in vitro proliferation and colony formation of human bone marrow progenitor cells.  93:273-279. 1996

Effect of commercial immunoglobulin G preparation on human monocyte Fc-receptor dependent binding of antibody coated platelets.  68:47-51. 1988

The Availability of Folates in Man: Effect of Orange Juice Supplement on Intestinal Conjugase.  32:123-134. 1976

The Availability of Food Folate in Man.  25:513-532. 1973